116 related articles for article (PubMed ID: 11812089)
1. Prognostic value of positron emission tomography using F-18-fluorodeoxyglucose in patients with cervical cancer undergoing radiotherapy.
Nakamoto Y; Eisbruch A; Achtyes ED; Sugawara Y; Reynolds KR; Johnston CM; Wahl RL
Gynecol Oncol; 2002 Feb; 84(2):289-95. PubMed ID: 11812089
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
3. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
[TBL] [Abstract][Full Text] [Related]
4. Metabolic response on post-therapy FDG-PET predicts patterns of failure after radiotherapy for cervical cancer.
Schwarz JK; Siegel BA; Dehdashti F; Grigsby PW
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):185-90. PubMed ID: 22014958
[TBL] [Abstract][Full Text] [Related]
5. Detection of early recurrence with 18F-FDG PET in patients with cervical cancer.
Ryu SY; Kim MH; Choi SC; Choi CW; Lee KH
J Nucl Med; 2003 Mar; 44(3):347-52. PubMed ID: 12620999
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.
Yen TC; See LC; Lai CH; Yah-Huei CW; Ng KK; Ma SY; Lin WJ; Chen JT; Chen WJ; Lai CR; Hsueh S
J Nucl Med; 2004 Jan; 45(1):22-9. PubMed ID: 14734665
[TBL] [Abstract][Full Text] [Related]
7. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
8. Improved prognostic value of 18F-FDG PET using a simple visual analysis of tumor characteristics in patients with cervical cancer.
Miller TR; Pinkus E; Dehdashti F; Grigsby PW
J Nucl Med; 2003 Feb; 44(2):192-7. PubMed ID: 12571208
[TBL] [Abstract][Full Text] [Related]
9. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome.
Grigsby PW; Siegel BA; Dehdashti F; Rader J; Zoberi I
J Clin Oncol; 2004 Jun; 22(11):2167-71. PubMed ID: 15169804
[TBL] [Abstract][Full Text] [Related]
10. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
11. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET.
Torizuka T; Kanno T; Futatsubashi M; Okada H; Yoshikawa E; Nakamura F; Takekuma M; Maeda M; Ouchi Y
J Nucl Med; 2003 Jul; 44(7):1051-6. PubMed ID: 12843219
[TBL] [Abstract][Full Text] [Related]
12. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival.
Kidd EA; Siegel BA; Dehdashti F; Grigsby PW
Cancer; 2007 Oct; 110(8):1738-44. PubMed ID: 17786947
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
[TBL] [Abstract][Full Text] [Related]
14. The role of PET scanning in the detection of recurrent cervical cancer.
Havrilesky LJ; Wong TZ; Secord AA; Berchuck A; Clarke-Pearson DL; Jones EL
Gynecol Oncol; 2003 Jul; 90(1):186-90. PubMed ID: 12821362
[TBL] [Abstract][Full Text] [Related]
15. The role of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG-PET) in the diagnosis of recurrence and lymph node metastasis of cervical cancer.
Umesaki N; Tanaka T; Miyama M; Kawabe J; Okamura T; Koyama K; Ochi H; Ogita S
Oncol Rep; 2000; 7(6):1261-4. PubMed ID: 11032926
[TBL] [Abstract][Full Text] [Related]
16. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy.
Xue F; Lin LL; Dehdashti F; Miller TR; Siegel BA; Grigsby PW
Gynecol Oncol; 2006 Apr; 101(1):147-51. PubMed ID: 16263155
[TBL] [Abstract][Full Text] [Related]
17. Roles of posttherapy
Liu FY; Su TP; Wang CC; Chao A; Chou HH; Chang YC; Yen TC; Lai CH
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1197-1204. PubMed ID: 29470614
[TBL] [Abstract][Full Text] [Related]
18. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
19. Diagnosis of recurrent uterine cervical cancer: computed tomography versus positron emission tomography.
Park DH; Kim KH; Park SY; Lee BH; Choi CW; Chin SY
Korean J Radiol; 2000; 1(1):51-5. PubMed ID: 11752929
[TBL] [Abstract][Full Text] [Related]
20. Posttherapy surveillance monitoring of cervical cancer by FDG-PET.
Grigsby PW; Siegel BA; Dehdashti F; Mutch DG
Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):907-13. PubMed ID: 12605968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]